Table 1.
Demographic and clinical characteristics by study group
| Total sample | HCV−/SUD− | HCV+/SUD− | HCV+/SUD+ | p Value | |
|---|---|---|---|---|---|
| Total N | 119 | 56 | 24 | 39 | |
| Demographics | |||||
| Age (mean years ± SD) | 53.81 ± 8.55 | 54.02 ± 11.41 | 53.04 ± 5.55 | 53.97 ± 4.42 | .888 |
| Male gender | 106 (89.1%) | 46 (82.1%)a | 21 (87.5%)b | 39 (100.0%)ab | .023 |
| Caucasian | 109 (91.6%) | 52 (92.9%) | 21 (87.5%) | 36 (92.3%) | .719 |
| Years of education (mean ± SD) | 14.55 ± 2.38 | 15.71 ± 2.68ab | 13.92 ± 1.67a | 13.26 ± 1.23b | <.001 |
| Psychiatric history | |||||
| Current psychiatric diagnosis | 55 (46.2%) | 24 (42.9%) | 9 (37.5%) | 22 (56.4%) | .273 |
| Mood disorder | 46 (38.7%) | 21 (37.5%) | 8 (33.3%) | 17 (43.6%) | .700 |
| PTSD | 22 (18.5%) | 10 (17.9%) | 5 (20.8%) | 7 (17.9%) | .947 |
| Other anxiety disorder | 18 (15.1%) | 9 (16.1%) | 3 (12.5%) | 6 (15.4%) | .919 |
| Medical history | |||||
| Current medical diagnosis | 65 (54.6%) | 33 (58.9%) | 13 (54.2%) | 19 (48.7%) | .618 |
| Diabetes | 18 (15.1%) | 12 (21.4%) | 1 (4.2%) | 5 (12.8%) | .128 |
| Hyperlipidemia | 27 (22.7%) | 17 (30.4%) | 3 (12.5%) | 7 (17.9%) | .152 |
| Hypertension | 35 (29.4%) | 20 (35.7%) | 9 (37.5%) | 6 (15.4%) | .065 |
| Cardiovascular disease | 12 (10.1%) | 7 (12.5%) | 2 (8.3%) | 3 (7.7%) | .711 |
| Asthma/pulmonary | 16 (13.4%) | 5 (8.9%) | 4 (16.7%) | 7 (17.9%) | .395 |
| Kidney dysfunction | 2 (1.7%) | 1 (1.8%) | 0 (0.0%) | 1 (2.6%) | .743 |
| Thyroid dysfunction | 7 (5.9%) | 3 (5.4%) | 1 (4.2%) | 3 (7.7%) | .826 |
Note. Data expressed as n, with (%) in terms of n over total N unless otherwise stated. Variables with the same superscript yielded significant univariate effects (p ≤ .05) using post hoc Scheffe tests. HCV = infected with chronic hepatitis C virus; PTSD = posttraumatic stress disorder; SD = standard deviation; SUD = history of substance use disorder, currently in remission.